drugset / Trial / NCT05593653

Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia

NCT05593653

Phase 4 Completed 31 enrolled Brigham and Women's Hospital
RandomizedCrossoverQuadruple-blindTreatment

Summary

The aim of this study is to determine if suvorexant can help treat the severity of insomnia and improve metabolic health in midlife women who had both insomnia and indicators of metabolic syndrome.

Timeline

Start
2023-01-06
Primary completion
2025-10-24
Completion
2025-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Suvorexant Small molecule 20 mg Oral